ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS
Oncotelic Therapeutics (OTCQB:OTLC) has announced its fourth publication in its TGFB2 research series. Clinical data revealed significant survival improvements in pancreatic cancer patients with low expression levels of both TGFB2 and either IRF9 or IFI27, extending median overall survival from 16-20 months to 72 months. This validates the therapeutic potential of targeting IRF9 and IFI27 knockdown in TGFB2 therapeutics. The company has published four peer-reviewed articles focusing on TGFB2's role in various cancers, including pancreatic ductal adenocarcinoma, low-grade gliomas, and pediatric diffuse intrinsic pontine glioma.
Oncotelic Therapeutics (OTCQB:OTLC) ha annunciato la sua quarta pubblicazione nella serie di ricerche su TGFB2. I dati clinici hanno rivelato significativi miglioramenti nella sopravvivenza dei pazienti affetti da cancro pancreatico con bassi livelli di espressione sia di TGFB2 che di IRF9 o IFI27, estendendo la sopravvivenza mediana complessiva da 16-20 mesi a 72 mesi. Questo convalida il potenziale terapeutico della soppressione di IRF9 e IFI27 nelle terapie con TGFB2. L'azienda ha pubblicato quattro articoli revisionati da pari che si concentrano sul ruolo di TGFB2 in vari tipi di cancro, inclusi l'adenocarcinoma duttale pancreatico, i gliomi a basso grado e il glioma pontino intrinseco diffuso pediatrico.
Oncotelic Therapeutics (OTCQB:OTLC) ha anunciado su cuarta publicación en su serie de investigación sobre TGFB2. Los datos clínicos revelaron mejoras significativas en la supervivencia de pacientes con cáncer de páncreas con bajos niveles de expresión tanto de TGFB2 como de IRF9 o IFI27, extendiendo la supervivencia mediana general de 16-20 meses a 72 meses. Esto valida el potencial terapéutico de dirigirse a la reducción de IRF9 e IFI27 en las terapias con TGFB2. La compañía ha publicado cuatro artículos revisados por pares que se centran en el papel de TGFB2 en varios tipos de cáncer, incluidos el adenocarcinoma ductal pancreático, los gliomas de bajo grado y el glioma pontino intrínseco difuso pediátrico.
온코텔릭 테라퓨틱스(OTCQB:OTLC)는 TGFB2 연구 시리즈의 네 번째 출판물을 발표했습니다. 임상 데이터는 췌장암 환자에서 TGFB2와 IRF9 또는 IFI27의 두 가지 모두 낮은 발현 수준을 가진 경우의 생존율 개선을 나타냈습니다. 이는 중간 전체 생존 기간을 16-20개월에서 72개월로 연장한 것입니다. 이는 TGFB2 치료에서 IRF9 및 IFI27의 노크다운을 타겟팅하는 치료 잠재력을 검증합니다. 이 회사는 췌장 덕트 선암, 저급 신경교종 및 소아 확산 내재성 교뇌 종양을 포함한 다양한 암에서 TGFB2의 역할에 초점을 맞춘 네 개의 동료 검토 기사를 발표했습니다.
Oncotelic Therapeutics (OTCQB:OTLC) a annoncé sa quatrième publication dans sa série de recherches sur TGFB2. Les données cliniques ont révélé des améliorations significatives de la survie chez les patients atteints de cancer du pancréas présentant de faibles niveaux d'expression à la fois de TGFB2 et d'IRF9 ou d'IFI27, prolongeant la survie médiane globale de 16-20 mois à 72 mois. Cela valide le potentiel thérapeutique de cibler l'inhibition d'IRF9 et d'IFI27 dans les thérapies TGFB2. L'entreprise a publié quatre articles évalués par des pairs, mettant l'accent sur le rôle de TGFB2 dans divers cancers, y compris l'adénocarcinome canalaire pancréatique, les gliomes de bas grade et le gliome pontin intrinsèquement diffus pédiatrique.
Oncotelic Therapeutics (OTCQB:OTLC) hat die vierte Veröffentlichung in seiner TGFB2-Forschungsreihe angekündigt. Klinische Daten zeigten signifikante Überlebensverbesserungen bei Pankreaskrebs-Patienten, die niedrige Expressionsniveaus sowohl von TGFB2 als auch von IRF9 oder IFI27 aufwiesen, wobei die mediane Gesamtüberlebenszeit von 16-20 Monaten auf 72 Monate verlängert wurde. Dies validiert das therapeutische Potenzial der Zielsetzung der IRF9- und IFI27-Reduktion in der TGFB2-Therapie. Das Unternehmen hat vier begutachtete Artikel veröffentlicht, die sich mit der Rolle von TGFB2 in verschiedenen Krebsarten befassen, einschließlich des duktalen Pankreasadenokarzinoms, niedriggradiger Gliome und pädiatrischen diffusen intrinsischen Pontin-Gliomen.
- Clinical data shows significant survival improvement from 16-20 months to 72 months in pancreatic cancer patients
- Validation of IRF9 and IFI27 as therapeutic targets
- Publication of four peer-reviewed articles demonstrating scientific validation
- None.
AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targets for TGFB2 therapeutics. https://www.mdpi.com/3003472
The publications of this series are available at Pubmed as follow:
1) TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. Qazi S, Trieu V. Int J Mol Sci. 2024 Oct 18;25(20):11221. doi: 10.3390/ijms252011221. PMID: 39457004
2) Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V, Maida AE, Qazi S. Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. PMID: 38539537 Free PMC article.
3) Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. Qazi S, Talebi Z, Trieu V. Biomedicines. 2024 Jan 15;12(1):191. doi: 10.3390/biomedicines12010191. PMID: 38255296 Free PMC article.
4) High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Uckun FM, Qazi S, Trieu V. Cancers (Basel). 2023 Mar 9;15(6):1676. doi: 10.3390/cancers15061676. PMID: 36980562 Free PMC article.
Additional information on our current phase 3 can be found at: https://www.youtube.com/watch?v=5KqdbySDRKE
About Oncotelic
Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.
Contact Information:
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com
FAQ
What were the survival improvements shown in Oncotelic's (OTLC) TGFB2 study for pancreatic cancer patients?
How many publications has Oncotelic (OTLC) released in their TGFB2 series as of October 2024?
What are the therapeutic targets validated in Oncotelic's (OTLC) latest TGFB2 research?
